XECHEM International INC
WKN: 548177 / ISIN: US9838953019XKEM aktuel empfohlen unter:
24.11.06 10:16
#677
petruss
Ja
sorry. Meinte natürlich 0,027...:)
ASK steht heute bei 0,017! Aber dafür gebe ich meine Aktien nicht her! Ich will die 0,018 sehen:)
ASK steht heute bei 0,017! Aber dafür gebe ich meine Aktien nicht her! Ich will die 0,018 sehen:)
24.11.06 14:46
#678
reinerla
hi petruss!
ja d zieht zur zeit gar nicht mit...
denke auch das wir nächste woche noch mal was hören müssten!
ja freitag ist xkem tag :)
hat aber heute nur den halben tag offen !
schauen wir mal...
allen viel glück hier!
denke auch das wir nächste woche noch mal was hören müssten!
ja freitag ist xkem tag :)
hat aber heute nur den halben tag offen !
schauen wir mal...
allen viel glück hier!
27.11.06 18:19
#682
petruss
Also
ich bin Bullish letzten Monat gab es die 0,034€! Das wären bei einem Einstieg zu 0,015€ über 100%. Also ich bleibe mal dabei.
29.11.06 16:48
#683
petruss
Hallo! Hier passiert
gerade was, ASK schon 0,019 mein EK war 0,015 Hm... Kommen News?
30.11.06 15:45
#685
ostseebrise.
XECHEM INTERNATIONAL INC Financials
http://finance.yahoo.com/q/is?s=xkem.ob
.......................................
That’s it... let’s make some money now!
.......................................
That’s it... let’s make some money now!
05.12.06 14:08
#688
petruss
Hatte gestern eine Order
zu 0,005!!! :) Würde mal abwarten wie weit der Kurs rutscht. Wegen einem Teilverkauf sitze ich jetzt auf 25000Stk.
05.12.06 18:52
#689
petruss
Unglaublich
von wen man hier im Thread grüne Sterne bekommt. Hier lesen wohl einige mit...
05.12.06 22:18
#690
reinerla
na wenn hier viele mitlesen-
dann wählt hier mal noch schnell fürn dr. pandey!
ist morgen zu ende und es sieht sehr gut aus fürn pandey!
http://www.marketwatch.com/ceooftheyear/2006/...d=djm_ceovotemktwmjr.
ist morgen zu ende und es sieht sehr gut aus fürn pandey!
http://www.marketwatch.com/ceooftheyear/2006/...d=djm_ceovotemktwmjr.
05.12.06 22:27
#692
reinerla
jo!
sieht gut aus!und wie gesagt heute die letzte möglichkeit noch zu wählen!
Here are the latest vote counts for all CEO's. I explained in a post two nights ago how I arrive at these numbers. Since public votes alone do not make up all the criteria, our good Dr. is not a shoe-in here, but at least he may have the popular vote.
Warren Buffett 6558 votes
John Chambers 2861 votes
Mathew Ferguson 1992 votes
Mark Hurd 2860 votes
Jeffrey Immelt 1558 votes
Steve Jobs 7291 votes
John Mack 1799 votes
Ramesh Pandey 9826 votes
James D. Sinegal 5480 votes
G. Richard Wagoner, JR. 2435 votes
Here are the latest vote counts for all CEO's. I explained in a post two nights ago how I arrive at these numbers. Since public votes alone do not make up all the criteria, our good Dr. is not a shoe-in here, but at least he may have the popular vote.
Warren Buffett 6558 votes
John Chambers 2861 votes
Mathew Ferguson 1992 votes
Mark Hurd 2860 votes
Jeffrey Immelt 1558 votes
Steve Jobs 7291 votes
John Mack 1799 votes
Ramesh Pandey 9826 votes
James D. Sinegal 5480 votes
G. Richard Wagoner, JR. 2435 votes
05.12.06 23:15
#693
reinerla
LOL!
http://www.investorshub.com/boards/read_msg.asp?message_id=15308724
schönen abend euch noch und danke für das sternchen... :)
schönen abend euch noch und danke für das sternchen... :)
07.12.06 15:46
#694
petruss
2006-12-07 06:30 ET - News Release
Xechem CEO Dr. Ramesh Pandey Wins the MarketWatch Readers' Choice 2006 CEO of the Year Award
2006-12-07 06:30 ET - News Release
NEW BRUNSWICK, N.J. -- (Business Wire)
The Chairman and CEO of Xechem International, Inc. (OTC BB: XKEM), Dr. Ramesh Pandey, was named Marketwatch Readers’ Choice 2006 CEO of the year, just ahead of Steve Jobs of Apple Computer, with Warren Buffet of Berkshire Hathaway a close third.
Xechem International had a watershed year in 2006. In July, Xechem successfully launched NICOSAN™, its breakthrough drug for the prophylactic management of Sickle Cell Disease in Nigeria. Nigeria has the highest incidence of Sickle Cell Disease in the world, with approximately 4 million people affected. The drug was approved by Nigerian drug regulatory authority NAFDAC, on July 3rd, 2006, and was launched just a few days later at a ceremony in Abuja, Nigeria presided over by His Excellency, Chief Olusegun Obasanjo, the President of Nigeria. NICOSAN™ is currently being sold in Nigeria. Xechem is conducting the necessary studies for the submission of an Investigational New Drug (IND) application to the FDA to start Clinical Trials in the USA and Europe in 2007. The year also witnessed the ground-breaking for what will be Xechem’s state-of-the-art FDA/cGMP-compliant factory in Abuja for the full commercial scale production of NICOSAN™. The facility is scheduled to be operational in 2007.
Dr. Pandey commented, “While I am honored to have won the MarketWatch Readers’ Choice 2006 CEO of the Year Award, particularly given the impressive group of accomplished and renowned executives named as finalists for this award, what is really motivating me is how close Xechem International is to making a crucial health difference to millions of sufferers of Sickle Cell Disease, first in Nigeria, and eventually throughout the world. We have made enormous progress toward this goal in 2006, and I want to personally thank MarketWatch’s readers for recognizing my efforts by honoring me with this prestigious award. I would also like to thank each and every shareholder for their votes, support and confidence in me.”
About NICOSAN™
NICOSAN™ is an anti-sickling drug developed by Nigerian scientists at the National Institute for Pharmaceutical Research and Development (NIPRD). In clinical studies conducted under NIPRD’s auspices, the drug has shown to substantially reduce the degree of sickling of the red blood cells of those afflicted with the disease. While not a cure, the clinical trials have confirmed that the large majority of patients taking NICOSAN™ no longer experience sickle cell “crises” while on the medication, and even among those whose crises are not eliminated, the number and severity of the crises are substantially reduced.
About Xechem
Xechem International is a development stage biopharmaceutical company working on Sickle Cell Disease (SCD), antidiabetic, antimalarial, antibacterial, antifungal, anticancer and antiviral (including AIDS) products from natural sources, including microbial and marine organisms. Its focus is on the development of phyto-pharmaceuticals (Natural Herbal Drugs) and other proprietary technologies, including those used in the treatment of orphan diseases. Xechem’s mission is to bring relief to the millions of people who suffer from these diseases. Its recent focus and resources have been directed primarily toward the development and launch of NICOSAN™ (to be marketed as HEMOXIN™ in the US and Europe). With the Nigerian regulatory approval now in hand, Xechem is now working on the commercialization of the drug in Nigeria and the pursuit of US FDA and European regulatory approval. In addition to NICOSAN™, Xechem is also working on another sickle cell compound, 5-HMF, which it has licensed from Virginia Commonwealth University (VCU).
Forward Looking Statements
This press release contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby.Such forward-looking statements involve known and unknown risks and uncertainties.
Contacts:
Xechem International, Inc.
Stephen Burg, 707-425-8855
Director
2006-12-07 06:30 ET - News Release
NEW BRUNSWICK, N.J. -- (Business Wire)
The Chairman and CEO of Xechem International, Inc. (OTC BB: XKEM), Dr. Ramesh Pandey, was named Marketwatch Readers’ Choice 2006 CEO of the year, just ahead of Steve Jobs of Apple Computer, with Warren Buffet of Berkshire Hathaway a close third.
Xechem International had a watershed year in 2006. In July, Xechem successfully launched NICOSAN™, its breakthrough drug for the prophylactic management of Sickle Cell Disease in Nigeria. Nigeria has the highest incidence of Sickle Cell Disease in the world, with approximately 4 million people affected. The drug was approved by Nigerian drug regulatory authority NAFDAC, on July 3rd, 2006, and was launched just a few days later at a ceremony in Abuja, Nigeria presided over by His Excellency, Chief Olusegun Obasanjo, the President of Nigeria. NICOSAN™ is currently being sold in Nigeria. Xechem is conducting the necessary studies for the submission of an Investigational New Drug (IND) application to the FDA to start Clinical Trials in the USA and Europe in 2007. The year also witnessed the ground-breaking for what will be Xechem’s state-of-the-art FDA/cGMP-compliant factory in Abuja for the full commercial scale production of NICOSAN™. The facility is scheduled to be operational in 2007.
Dr. Pandey commented, “While I am honored to have won the MarketWatch Readers’ Choice 2006 CEO of the Year Award, particularly given the impressive group of accomplished and renowned executives named as finalists for this award, what is really motivating me is how close Xechem International is to making a crucial health difference to millions of sufferers of Sickle Cell Disease, first in Nigeria, and eventually throughout the world. We have made enormous progress toward this goal in 2006, and I want to personally thank MarketWatch’s readers for recognizing my efforts by honoring me with this prestigious award. I would also like to thank each and every shareholder for their votes, support and confidence in me.”
About NICOSAN™
NICOSAN™ is an anti-sickling drug developed by Nigerian scientists at the National Institute for Pharmaceutical Research and Development (NIPRD). In clinical studies conducted under NIPRD’s auspices, the drug has shown to substantially reduce the degree of sickling of the red blood cells of those afflicted with the disease. While not a cure, the clinical trials have confirmed that the large majority of patients taking NICOSAN™ no longer experience sickle cell “crises” while on the medication, and even among those whose crises are not eliminated, the number and severity of the crises are substantially reduced.
About Xechem
Xechem International is a development stage biopharmaceutical company working on Sickle Cell Disease (SCD), antidiabetic, antimalarial, antibacterial, antifungal, anticancer and antiviral (including AIDS) products from natural sources, including microbial and marine organisms. Its focus is on the development of phyto-pharmaceuticals (Natural Herbal Drugs) and other proprietary technologies, including those used in the treatment of orphan diseases. Xechem’s mission is to bring relief to the millions of people who suffer from these diseases. Its recent focus and resources have been directed primarily toward the development and launch of NICOSAN™ (to be marketed as HEMOXIN™ in the US and Europe). With the Nigerian regulatory approval now in hand, Xechem is now working on the commercialization of the drug in Nigeria and the pursuit of US FDA and European regulatory approval. In addition to NICOSAN™, Xechem is also working on another sickle cell compound, 5-HMF, which it has licensed from Virginia Commonwealth University (VCU).
Forward Looking Statements
This press release contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby.Such forward-looking statements involve known and unknown risks and uncertainties.
Contacts:
Xechem International, Inc.
Stephen Burg, 707-425-8855
Director
07.12.06 16:13
#697
Limitless
ja, drüben übern teich
bei uns sind alle auf dem weihnachtsmarkt! limi
07.12.06 16:22
#698
reinerla
noch 4 Handelstage!:))
10th Annual
Biotech/Specialty Pharma Conference
DATE December 12–13, 2006
TIME Day One 8:30 a.m.–5:10 p.m.
Day Two 8:30 a.m.–4:30 p.m.
3:10 Xechem International, Inc. (OTCBB: XKEM)
Ramesh C. Pandey, PhD, Chairman and CEO
Xechem International, a biopharmaceutical company, is engaged in developing drugs for sickle cell disease, malaria, AIDS, and cancer from natural sources.
http://www.nyssa.org/...tManagement/ContentDisplay.cfm&ContentID=8897
Biotech/Specialty Pharma Conference
DATE December 12–13, 2006
TIME Day One 8:30 a.m.–5:10 p.m.
Day Two 8:30 a.m.–4:30 p.m.
3:10 Xechem International, Inc. (OTCBB: XKEM)
Ramesh C. Pandey, PhD, Chairman and CEO
Xechem International, a biopharmaceutical company, is engaged in developing drugs for sickle cell disease, malaria, AIDS, and cancer from natural sources.
http://www.nyssa.org/...tManagement/ContentDisplay.cfm&ContentID=8897
07.12.06 16:40
#699
Limitless
Einladung?
tja, petruss,da hätteste ja mal die damen des bords als aktionär einladen können!
"New York Society of Security Analysts (NYSSA)
1177 Avenue of the Americas, 2nd Floor (between 45th and 46th Streets), NYC
Due to tight building security, all members must inform NYSSA staff of their intention to use the member facilities by 5:00 p.m. the day before you intend to visit. Please send an email to guest@nyssa.org or call our receptionist at 212-541-4530 ext. 10, specify your name, firm and time of visit. Please be prepared to show a photo ID to enter the building. "
hmmm... die sind ja vorsichtig! limi
"New York Society of Security Analysts (NYSSA)
1177 Avenue of the Americas, 2nd Floor (between 45th and 46th Streets), NYC
Due to tight building security, all members must inform NYSSA staff of their intention to use the member facilities by 5:00 p.m. the day before you intend to visit. Please send an email to guest@nyssa.org or call our receptionist at 212-541-4530 ext. 10, specify your name, firm and time of visit. Please be prepared to show a photo ID to enter the building. "
hmmm... die sind ja vorsichtig! limi
07.12.06 16:44
#700
petruss
Wenn das alles
solche Chemieschnallen sind, lieber net. Dann lieber alle Damen von Ariva!:)